Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
HHS awards BioShield contract for AVA anthrax vaccine
June 6th, 2005
The U.S. Department of Health and Human Services (HHS) awarded a $122.7 million contract to BioPort Corp. of Lansing, Michigan, for the manufacture and delivery of 5 million doses of Anthrax Vaccine Adsorbed (AVA), a licensed anthrax vaccine. This supply of AVA anthrax vaccine, which is being purchased under the Project BioShield program, will be placed in the nation's Strategic National Stockpile where it will be available for use in the event of a bioterror anthrax incident. Together with the existing stockpile of antibiotics, these medical countermeasures represent a critical component of the president's strategy for biodefense in the 21st...
Source: Biotech Business Week (2005-06-06)
|
